AP NEWS

Cancer Anorexia-Cachexia Syndrome Pipeline Review, H2 2018: Therapeutic Analysis of 15 Companies & Drug Profiles - ResearchAndMarkets.com

October 9, 2018

DUBLIN--(BUSINESS WIRE)--Oct 9, 2018--The “Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Cancer Anorexia-Cachexia Syndrome - Overview Cancer Anorexia-Cachexia Syndrome - Therapeutics Development Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development Cancer Anorexia-Cachexia Syndrome - Drug Profiles Cancer Anorexia-Cachexia Syndrome - Dormant Projects Cancer Anorexia-Cachexia Syndrome - Discontinued Products Cancer Anorexia-Cachexia Syndrome - Product Development Milestones Appendix

Companies Mentioned

Abreos Biosciences Inc Aeterna Zentaris Inc Aphios Corp Energenesis Biomedical Co Ltd Fountain Biopharma Inc Incyte Corp NGM Biopharmaceuticals Inc Novartis AG Paradigm Biopharmaceuticals Ltd RaQualia Pharma Inc Teijin Pharma Ltd Vascular BioSciences Viking Therapeutics Inc XBiotech Inc Zeria Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/v67r7n/cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181009005955/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/09/2018 12:43 PM/DISC: 10/09/2018 12:43 PM

http://www.businesswire.com/news/home/20181009005955/en

AP RADIO
Update hourly